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Abstract
Introduction: Three-dimensional techniques for radiotherapy have expanded possibilities for
partial volume liver radiotherapy. Characteristic, transient radiographic changes can occur in the
absence of clinical radiation-induced liver disease after hepatic radiotherapy and must be
distinguished from local recurrence.
Case presentation: In this report, we describe computed tomography changes after
chemoradiotherapy for cholangiocarcinoma as an example of collaboration to determine the
clinical significance of the radiographic finding.
Conclusion:  Because of improved three-dimensional, conformal radiotherapy techniques,
consultation across disciplines may be necessary to interpret post-treatment imaging findings.
Introduction
Conformal radiotherapy (RT) techniques allow for the
delivery of high radiation doses to fields encompassing
partial liver volumes as a component of combined modal-
ity cancer treatment. RT doses are limited by concerns for
radiation-induced liver disease (RILD) [1]. Imaging
changes may occur after treatment, in the absence of treat-
ment-related toxicity, and must be distinguished from
possible disease recurrence. In this report, we describe CT
changes after chemoradiotherapy for cholangiocarcinoma
as an example of the challenge of distinguishing treatment
effect from disease recurrence.
Case presentation
A 40-year-old female presented with a one-month history
of diffuse pruritus that failed to resolve with antihista-
mines. She developed right upper quadrant abdominal
pain and jaundice. Contrast-enhanced magnetic reso-
nance imaging (MRI) demonstrated a 2.1 × 1.6 cm porta
hepatis mass involving the common bile duct (CBD) with
ductal dilatation (Fig. 1). Endoscopic retrograde cholangi-
opancreatography revealed an irregular CBD with stricture
of the proximal common hepatic duct at the level of the
hepatic duct bifurcation. Biliary decompression was
achieved through preoperative stent placement. Imaging
studies revealed no evidence of regional lymphadenopa-
thy or distant metastases.
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During exploratory laparotomy, palpation of the com-
mon bile duct revealed an obvious mass in the common
hepatic duct region above the termination of the cystic
duct. Neither hepatic dissemination nor regional lym-
phadenopathy was noted, and the surgeon proceeded to
perform a cholecystectomy, choledochectomy, hepatico-
jejunostomy and reconstruction of the biliary enteric sys-
tem. Adequate biliary drainage was achieved. Surgical
pathology showed a poorly differentiated adenocarci-
noma of the common bile duct, measuring 1.6 cm in
greatest dimension. Resection margins were negative.
Tumor cells infiltrated the fibromuscular layer of the
hepatic duct with extension into the surrounding connec-
tive tissue, and all lymph nodes were negative. The patient
was staged as IB (T2N0M0) cholangiocarcinoma, and was
recommended to receive concurrent combined modality
therapy consisting of capecitabine 1500 mg twice daily
and external beam RT to a total dose of 50.4 Gy delivered
in 28 daily fractions of 1.8 Gy. A CT was performed for RT
treatment planning, and three-dimensional techniques
were used to develop a four-field conformal plan. The
50.4 Gy isodose line displayed on the treatment planning
CT (Fig. 2) represents the borders of the treated volume
that received the prescribed dose.
On routine follow-up three months after completing
chemoradiation, the patient was asymptomatic and had
returned to work full-time. Laboratory values were within
normal limits. At this time, a CT scan of the abdomen and
pelvis showed a low attenuation region in the liver with
linear margins (Fig. 3A). The radiation oncologist was
consulted to assist in evaluating the radiographic abnor-
mality in order to distinguish post-radiation changes from
local recurrence. When compared to the CT obtained for
treatment planning (Fig. 2), the tomographic changes cor-
respond closely to the radiation prescription isodose line.
In order to verify that the imaging abnormality corre-
sponded to the radiation portal, the radiation treatment
planning CT and the follow-up diagnostic CT were co-reg-
istered using anatomical landmarks to confirm that the
low-density region corresponded to the 50.4 Gy isodose
line. Subsequently, the patient developed neither clinical
hepatic toxicity nor disease recurrence. A CT scan
obtained six months later (Fig. 3B) demonstrated nearly
complete resolution of the previously observed post-RT
hepatic parenchymal changes, with interval loss of hepatic
volume and development of surface nodularity consistent
with evolving post-RT changes with local fibrosis.
Discussion
Conformal RT techniques may produce imaging changes
that must be distinguished from disease recurrence.
Although RT to the entire liver is known to produce clini-
cal hepatic toxicity at doses of 30 to 35 Gy in standard
fractionation, three-dimensional conformal planning
techniques allow delivery of higher radiation doses to par-
tial liver target volumes [1-3]. Current methods closely
appose regions of high and low dose by escalating dose to
the treatment volume and minimizing exposure to adja-
cent normal hepatic parenchyma [4]. Yamasaki et al.
reviewed contrast-enhanced CT studies from 31 patients
who received high-dose conformal radiation therapy to a
partial liver volume and found minimal correlation
between radiation-induced tomographic changes and
clinical radiation hepatitis, which was observed in only
6% of subjects. 74% of patients studied displayed regions
Axial image of CT scan performed with IV contrast for radia- tion treatment planning Figure 2
Axial image of CT scan performed with IV contrast for radia-
tion treatment planning. The solid line marks the region that 
received at least 50.4 Gy during the radiotherapy course.
Axial T1, fat-suppressed, portal venous phase MRI performed  prior to resection Figure 1
Axial T1, fat-suppressed, portal venous phase MRI performed 
prior to resection. Arrows define the boundaries of the 
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of low attenuation in treatment volume in post-treatment
CT scans, but no scans showed linear margins [5]. The
absence of crisp margins of attenuation may be explained
by the use of nonaxial, noncoplanar overlapping fields in
the study, in contrast to the four-field coplanar plan pre-
sented in this case. Other CT changes after partial volume
hepatic radiation range from linear regions of low density
corresponding to parallel opposed portals [6,7] to a
peripheral, curved band of low attenuation in the upper
liver after intensity-modulated radiation therapy for mes-
othelioma [8].
Imaging changes after chemoradiation of the liver are a
separate entity distinct from RILD, a syndrome distin-
guished by the clinical triad of hepagatomegaly, ascites,
and elevated liver enzymes, predominantly alkaline phos-
phatase. Although RILD may produce hepatic failure,
most cases resolve within three months after radiation [4].
The pathologic features of RILD include severe central
venous congestion of hepatic lobules, relative sparing of
larger veins, and endothelial damage in small veins
[4,9,10]. Clinically, RILD is similar to Budd-Chiari syn-
drome, but with sparing of larger veins such as the vena
cava. Although RILD occurs with conventional radiation
techniques [1-3], RT fields encompassing the whole liver
may be safely delivered if the mean liver dose remains
below 30 to 37 Gy [4,11,12]. Multiple three-dimensional
models exist to predict tolerance of the liver to higher
doses of partial volume radiation [4].
Imaging changes after partial volume hepatic radiation are
usually subclinical and do not predict RILD [5]. In addi-
tion to CT changes involving the treated region after RT,
other imaging findings include T1 hypointensity, T2
hyperintensity, and sustained contrast enhancement on
MRI [13]; decreased echogenicity on ultrasound [14]; and
decreased uptake of particulate reticuloendothelial con-
trast [15]. Collectively, imaging changes after hepatic RT
may display the effects of edema or vascular congestion,
consistent with a proposed vascular etiology for radiation-
induced liver damage.
Conclusion
Three-dimensional techniques for RT planning and deliv-
ery have expanded the possibilities for high-dose partial
volume liver RT. Characteristic, transient radiographic
changes occur in the absence of clinical RILD after hepatic
RT and must be distinguished from recurrent disease on
follow-up imaging studies. Because of the complexity of
radiation treatment techniques, consultation across disci-
plines may be necessary to determine the significance of
post-treatment imaging findings.
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(A) Contrast-enhanced CT scan performed three months after completion of chemoradiotherapy Figure 3
(A) Contrast-enhanced CT scan performed three months after completion of chemoradiotherapy. The arrows highlight the 
linear margins of the region of low attenuation. (B) CT obtained 9 months after radiation treatment. Oral and IV contrast 
were administered. The previously observed low attenuation region has resolved.
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